Home  /  Resource Library  /  Zanbrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line treatment for non-GCB diffuse large B-cell lymphoma: An updated analysis of efficacy and tolerability

Zanbrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line treatment for non-GCB diffuse large B-cell lymphoma: An updated analysis of efficacy and tolerability

ICML 2023